Profile data is unavailable for this security.
About the company
Formycon AG is a Germany-based company engaged in providing biosimilar drugs and formulations. Its business activities are focused on the development and marketing of biopharmaceuticals that are similar to existing drugs, for which the patent protection is expiring. The Company focuses on treatments in the area of ophthalmology, immunology and other chronic diseases, covering all steps of biosimilar development process, from early-stage analysis of the originator drug to the preclinical and clinical testing phases, as well as the preparation of dossiers for marketing approval. Its biosimilar product pipeline consists of four candidates in pre-clinical and clinical testing phases, including FYB201, a biosimilar candidate for Lucentis; FYB202, a biosimilar candidate for Stelara; FYB203, a biosimilar candidate for Eylea, and FYB205.
- Revenue in EUR (TTM)68.64m
- Net income in EUR-42.24m
- Incorporated2012
- Employees224.00
- LocationFormycon AGFraunhoferstrasse 15MARTINSRIED 82152GermanyDEU
- Phone+49 89 864667100
- Fax+49 89 864667110
- Websitehttps://www.formycon.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Heidelberg Pharma AG | 9.86m | -20.35m | 139.81m | 95.00 | -- | 2.83 | -- | 14.18 | -0.4357 | -0.4357 | 0.2113 | 1.06 | 0.1154 | 0.4316 | 9.49 | 103,778.10 | -23.81 | -43.91 | -33.02 | -64.34 | 67.01 | 52.13 | -206.38 | -206.24 | 2.33 | -- | 0.1057 | -- | -46.75 | 21.87 | -3.27 | -- | -0.8341 | -- |
| PharmaSGP Holding SE | 97.55m | 14.99m | 259.20m | 85.00 | 17.30 | 7.08 | 10.64 | 2.66 | 1.25 | 1.25 | 8.13 | 3.05 | 0.7592 | 1.15 | 9.69 | 1,234,848.00 | 11.67 | 14.62 | 13.98 | 21.22 | 90.61 | 89.90 | 15.37 | 19.17 | 2.15 | 9.03 | 0.6809 | -- | 31.34 | 10.09 | 11.82 | 0.2886 | 14.67 | -- |
| Formycon AG | 68.64m | -42.24m | 674.49m | 224.00 | -- | 1.43 | -- | 9.83 | -2.80 | -2.80 | 4.41 | 26.65 | 0.079 | 91.54 | 2.24 | 334,839.00 | -4.86 | 3.03 | -5.17 | 3.29 | 35.52 | 31.61 | -61.53 | 10.91 | 1.00 | -- | 0.0202 | 0.00 | 16.07 | 7.86 | 370.82 | -- | 120.72 | -- |
| Eckert & Ziegler SE | 246.09m | 30.01m | 768.54m | 1.08k | 25.21 | 3.40 | 17.52 | 3.12 | 1.44 | 1.26 | 11.81 | 10.67 | 0.5812 | 3.28 | 5.63 | 228,923.70 | 7.20 | 8.50 | 8.67 | 10.23 | 47.29 | 48.61 | 12.39 | 14.00 | 2.31 | 12.77 | 0.2008 | 35.09 | 10.74 | 7.84 | -2.84 | 13.22 | 33.82 | -30.12 |
| Biotest AG | 684.60m | 127.00m | 1.40bn | 2.43k | 13.02 | 3.32 | -- | 2.04 | 3.21 | 3.21 | 17.30 | 12.61 | 0.5238 | 1.13 | 3.84 | 282,192.90 | 9.72 | -0.0693 | 12.10 | -0.079 | 40.94 | 28.43 | 18.55 | -0.1527 | 0.8757 | 3.86 | 0.5803 | -- | 32.65 | 11.33 | 490.89 | -- | -9.36 | -- |
| Dermapharm Holding SE | 1.14bn | 62.37m | 1.76bn | 3.50k | 28.19 | 3.27 | 10.65 | 1.55 | 1.16 | 1.16 | 21.09 | 10.01 | 0.6354 | 1.44 | 12.10 | 324,664.30 | 3.39 | 8.68 | 4.10 | 10.06 | 63.34 | 61.94 | 5.33 | 12.31 | 0.7852 | 2.56 | 0.6647 | 54.69 | 10.79 | 14.68 | -53.54 | -3.70 | 9.85 | -- |
| Evotec SE | 820.80m | -94.98m | 2.43bn | 5.09k | -- | 2.12 | -- | 2.96 | -0.5371 | -0.5371 | 4.64 | 6.45 | 0.3634 | 19.15 | 5.44 | 165,751.60 | -4.21 | 2.35 | -5.08 | 2.83 | 26.78 | 25.86 | -11.57 | 6.22 | 2.09 | 0.0208 | 0.3404 | 0.00 | 21.59 | 23.29 | -181.51 | -- | 59.47 | -- |
| MorphoSys AG | 238.28m | -189.73m | 2.56bn | 524.00 | -- | 51.94 | -- | 10.72 | -5.58 | -5.58 | 6.94 | 1.30 | 0.1077 | 1.18 | 3.86 | 454,729.60 | -8.58 | -10.25 | -9.78 | -11.61 | 78.62 | 85.92 | -79.63 | -78.53 | 2.84 | -- | 0.8403 | -- | -14.37 | 25.53 | -25.60 | -- | 3.11 | -- |
| Holder | Shares | % Held |
|---|---|---|
| Active Ownership Corp SARLas of 17 Mar 2023 | 1.07m | 6.09% |
| Norges Bank Investment Managementas of 31 Dec 2023 | 151.00k | 0.86% |
| ACATIS Investment Kapitalverwaltungsgesellschaft mbHas of 29 Feb 2024 | 140.39k | 0.80% |
| Lupus alpha Asset Management AGas of 30 Jun 2023 | 118.00k | 0.67% |
| Plutos Verm�gensverwaltung AGas of 30 Sep 2023 | 110.00k | 0.62% |
| MPPM Manfred Piontke Portfolio Management e.K.as of 30 Sep 2022 | 43.50k | 0.25% |
| TBF Global Asset Management GmbHas of 31 Dec 2023 | 38.05k | 0.22% |
| BlackRock Fund Advisorsas of 04 Apr 2024 | 32.97k | 0.19% |
| GS&P Kapitalanlagegesellschaft SAas of 30 Jun 2023 | 32.50k | 0.18% |
| Ehrke & L�bberstedt AGas of 29 Feb 2024 | 29.08k | 0.17% |
